{"id":"capecitabine-xeloda","safety":{"commonSideEffects":[{"rate":"60","effect":"Hand-foot skin reaction (palmar-plantar erythrodysesthesia)"},{"rate":"55","effect":"Diarrhea"},{"rate":"35","effect":"Nausea"},{"rate":"25","effect":"Vomiting"},{"rate":"25","effect":"Stomatitis"},{"rate":"40","effect":"Fatigue"},{"rate":"3","effect":"Neutropenia"},{"rate":"1","effect":"Thrombocytopenia"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Capecitabine is an oral fluoropyrimidine carbamate that undergoes hepatic and tissue-level enzymatic conversion to 5-fluorouracil (5-FU). The active 5-FU metabolite inhibits thymidylate synthase, blocking dTMP synthesis and DNA replication, while also incorporating into RNA to disrupt protein synthesis. This mechanism preferentially affects rapidly dividing cancer cells.","oneSentence":"Capecitabine is a prodrug that is converted to fluorouracil in tumor tissue, where it inhibits thymidylate synthase and gets incorporated into DNA and RNA to disrupt cancer cell growth.","_ai_confidence":"high"},"_scrapedAt":"2026-03-27T23:31:45.661Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Metastatic colorectal cancer"},{"name":"Metastatic breast cancer"},{"name":"Gastric cancer"},{"name":"Pancreatic cancer"}]},"trialDetails":[{"nctId":"NCT06966700","phase":"PHASE3","title":"A Clinical Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in People With Breast Cancer (MK-2870-032)","status":"RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2025-06-30","conditions":"Breast Neoplasms, Triple Negative Breast Neoplasms, HR Low-Positive/HER2-Negative Breast Neoplasms","enrollment":2400},{"nctId":"NCT06312176","phase":"PHASE3","title":"A Study of Sacituzumab Tirumotecan (MK-2870) as a Single Agent and in Combination With Pembrolizumab (MK-3475) Versus Treatment of Physician's Choice in Participants With HR+/HER2- Unresectable Locally Advanced or Metastatic Breast Cancer (MK-2870-010)","status":"RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2024-04-14","conditions":"Breast Neoplasms","enrollment":1200},{"nctId":"NCT07060807","phase":"PHASE3","title":"A Clinical Study of Patritumab Deruxtecan to Treat Breast Cancer (MK-1022-016)","status":"RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2025-07-21","conditions":"Breast Neoplasms","enrollment":1000},{"nctId":"NCT06393374","phase":"PHASE3","title":"Sacituzumab Tirumotecan (MK-2870) Plus Pembrolizumab Versus TPC in TNBC Who Did Not Achieve pCR (MK-2870-012)","status":"RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2024-06-24","conditions":"Triple-Negative Breast Cancer","enrollment":1530},{"nctId":"NCT05629585","phase":"PHASE3","title":"A Study of Dato-DXd With or Without Durvalumab Versus Investigator's Choice of Therapy in Patients With Stage I-III Triple-negative Breast Cancer Without Pathological Complete Response Following Neoadjuvant Therapy (TROPION-Breast03)","status":"ACTIVE_NOT_RECRUITING","sponsor":"AstraZeneca","startDate":"2022-11-28","conditions":"Breast Cancer","enrollment":1174},{"nctId":"NCT06324357","phase":"PHASE1, PHASE2","title":"Beamion BCGC-1: A Study to Find a Suitable Dose of Zongertinib Used Alone and in Combination With Other Treatments to Test Whether it Helps People With Different Types of HER2+ Cancer That Has Spread","status":"RECRUITING","sponsor":"Boehringer Ingelheim","startDate":"2024-06-03","conditions":"Metastatic Breast Cancer, Metastatic Gastric Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma","enrollment":768},{"nctId":"NCT06469944","phase":"PHASE1, PHASE2","title":"Substudy 06C: A Study of Investigational Agents With Pembrolizumab (MK-3475) and Chemotherapy in Participants With First-Line Locally Advanced Unresectable/Metastatic Gastroesophageal Adenocarcinoma (MK-3475-06C/KEYMAKER-U06)","status":"RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2024-09-20","conditions":"Gastroesophageal Junction, Gastroesophageal Adenocarcinoma, Esophageal Neoplasms","enrollment":160},{"nctId":"NCT06797635","phase":"PHASE2","title":"Study of Patritumab Deruxtecan Plus Pembrolizumab With Other Anticancer Agents in Participants With High-Risk Early-Stage Triple-Negative or Hormone Receptor-Low Positive/HER-2 Negative Breast Cancer (MK-1022-010, HERTHENA-Breast-03)","status":"RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2025-03-20","conditions":"Breast Neoplasms, Breast Cancer","enrollment":372},{"nctId":"NCT04895358","phase":"PHASE3","title":"Study of Pembrolizumab (MK-3475) Plus Chemotherapy Versus Placebo Plus Chemotherapy for HR+/HER2- Locally Recurrent Inoperable or Metastatic Breast Cancer (MK-3475-B49/KEYNOTE-B49)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2021-06-18","conditions":"Breast Neoplasms","enrollment":340},{"nctId":"NCT03221426","phase":"PHASE3","title":"Study of Pembrolizumab (MK-3475) Plus Chemotherapy Versus Placebo Plus Chemotherapy in Participants With Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma (MK-3475-585/KEYNOTE-585)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2017-10-09","conditions":"Gastric Cancer, Gastroesophageal Junction Cancer","enrollment":1007},{"nctId":"NCT04882241","phase":"PHASE3","title":"Study of Pembrolizumab (MK-3475) Plus Chemotherapy Versus Placebo Plus Chemotherapy in Participants With Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma (MK-3475-585/KEYNOTE-585)-China Extension","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2020-07-29","conditions":"Gastric Cancer, Gastroesophageal Junction Cancer","enrollment":120},{"nctId":"NCT03675737","phase":"PHASE3","title":"Pembrolizumab (MK-3475) Plus Chemotherapy Versus Placebo Plus Chemotherapy in Participants Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma (MK-3475-859/KEYNOTE-859)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2018-11-08","conditions":"Stomach Neoplasms","enrollment":1579},{"nctId":"NCT05062317","phase":"PHASE2","title":"ctDNA-Directed Post-Hepatectomy Chemotherapy for Patients With Resectable Colorectal Liver Metastases","status":"RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2022-04-26","conditions":"Liver Metastases","enrollment":120},{"nctId":"NCT05633654","phase":"PHASE3","title":"Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's Choice in Patients With Triple Negative Breast Cancer Who Have Residual Invasive Disease After Surgery and Neoadjuvant Therapy (ASCENT-05/AFT-65 OptimICE-RD/GBG 119/NSABP B-63)","status":"RECRUITING","sponsor":"Gilead Sciences","startDate":"2022-12-12","conditions":"Triple Negative Breast Cancer","enrollment":1514},{"nctId":"NCT02595424","phase":"PHASE2","title":"Cisplatin and Etoposide Versus Temozolomide and Capecitabine in Patients With Advanced Poorly Differentiated (G3) Non-Small Cell Gastrointestinal Neuroendocrine Carcinomas","status":"ACTIVE_NOT_RECRUITING","sponsor":"ECOG-ACRIN Cancer Research Group","startDate":"2016-04-06","conditions":"Gastric Neuroendocrine Carcinoma, Intestinal Neuroendocrine Carcinoma, Pancreatic Neuroendocrine Carcinoma","enrollment":67},{"nctId":"NCT06112379","phase":"PHASE3","title":"A Phase III Randomised Study to Evaluate Dato-DXd and Durvalumab for Neoadjuvant/Adjuvant Treatment of Triple-Negative or Hormone Receptor-low/HER2-negative Breast Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"AstraZeneca","startDate":"2023-11-14","conditions":"Breast Cancer","enrollment":1902},{"nctId":"NCT02955940","phase":"PHASE2","title":"An Open-Label Study to Enable Continued Treatment Access for Subjects Previously Enrolled in Studies of Ruxolitinib","status":"ACTIVE_NOT_RECRUITING","sponsor":"Incyte Corporation","startDate":"2016-11-30","conditions":"Pancreatic Cancer, Colorectal Cancer (CRC), Breast Cancer","enrollment":10},{"nctId":"NCT04428151","phase":"PHASE2","title":"Lenvatinib (E7080/MK-7902) in Combination With Pembrolizumab (MK-3475) vs. Standard Chemotherapy and Lenvatinib Monotherapy in Participants With Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma That Progressed After Platinum Therapy and Immunotherapy (MK-7902-009/E7080-G000-228/LEAP-009)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2020-08-06","conditions":"Squamous Cell Carcinoma of Head and Neck","enrollment":408},{"nctId":"NCT05840211","phase":"PHASE3","title":"Study of Sacituzumab Govitecan Versus Treatment of Physician's Choice in Patients With Hormone Receptor-positive/Human Epidermal Growth Factor Receptor 2 Negative (HR+/HER2-) Metastatic Breast Cancer Who Have Received Endocrine Therapy","status":"ACTIVE_NOT_RECRUITING","sponsor":"Gilead Sciences","startDate":"2023-05-08","conditions":"Locally Advanced or Unresectable Metastatic Breast Cancer, Stage IV Breast Cancer","enrollment":654},{"nctId":"NCT02008656","phase":"PHASE2","title":"Trial Evaluating 3-year Disease Free Survival in Patients With Locally Advanced Rectal Cancer Treated With Chemoradiation Plus Induction or Consolidation Chemotherapy and Total Mesorectal Excision or Non-operative Management","status":"ACTIVE_NOT_RECRUITING","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2013-11","conditions":"Rectal Cancer","enrollment":358},{"nctId":"NCT05625412","phase":"PHASE1","title":"A Study of BMS-986360/CC-90001 Alone and in Combination With Chemotherapy or Nivolumab in Advanced Solid Tumors","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"2022-12-09","conditions":"Advanced Solid Tumors","enrollment":70},{"nctId":"NCT02492711","phase":"PHASE3","title":"Margetuximab Plus Chemotherapy vs Trastuzumab Plus Chemotherapy in the Treatment of HER2+ Metastatic Breast Cancer","status":"COMPLETED","sponsor":"MacroGenics","startDate":"2015-08-24","conditions":"HER-2 Positive Breast Cancer, Metastatic Neoplasm","enrollment":624},{"nctId":"NCT03563157","phase":"PHASE1, PHASE2","title":"QUILT 3.071: NANT Colorectal Cancer (CRC) Vaccine","status":"TERMINATED","sponsor":"ImmunityBio, Inc.","startDate":"2018-09-28","conditions":"Colorectal Cancer Metastatic, mCRC","enrollment":2},{"nctId":"NCT02009449","phase":"PHASE1","title":"A Phase 1 Study of Pegilodecakin (LY3500518) in Participants With Advanced Solid Tumors","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2013-11-15","conditions":"Melanoma, Prostate Cancer, Ovarian Cancer","enrollment":353},{"nctId":"NCT04456699","phase":"PHASE3","title":"Efficacy and Safety of Olaparib (MK-7339) With or Without Bevacizumab Compared to Bevacizumab With a Fluoropyrimidine in Unresectable or Metastatic Colorectal Cancer (CRC) (MK-7339-003/LYNK-003)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2020-08-19","conditions":"Metastatic Colorectal Cancer","enrollment":335},{"nctId":"NCT06110598","phase":"PHASE2","title":"CAPEcitabine eXtension of Adjuvant Therapy for Pancreatic Adenocarcinoma: (CAPE-X)","status":"WITHDRAWN","sponsor":"Case Comprehensive Cancer Center","startDate":"2024-12-01","conditions":"Pancreas Cancer, Pancreas Adenocarcinoma","enrollment":""},{"nctId":"NCT02735239","phase":"PHASE1, PHASE2","title":"Study of Anti-PD-L1 in Combination With Chemo(Radio)Therapy for Oesophageal Cancer","status":"COMPLETED","sponsor":"Ludwig Institute for Cancer Research","startDate":"2016-06-24","conditions":"Esophageal Cancer","enrollment":73},{"nctId":"NCT01679054","phase":"","title":"Cost-minimization Analysis of Gastric Cancer Treatments in Hong Kong","status":"COMPLETED","sponsor":"Vivian Wing Yan Lee","startDate":"2011-10","conditions":"Gastric Cancer","enrollment":58},{"nctId":"NCT05641246","phase":"PHASE2","title":"Effect of Topical Diclofenac on Clinical Outcome in Breast Cancer Patients Treated With Capecitabine","status":"COMPLETED","sponsor":"German University in Cairo","startDate":"2022-12-08","conditions":"Hand and Foot Syndrome","enrollment":86},{"nctId":"NCT02535988","phase":"PHASE2","title":"Abscopal Effect for Metastatic Colorectal Cancer","status":"WITHDRAWN","sponsor":"Zhejiang Provincial People's Hospital","startDate":"2015-09","conditions":"Colorectal Cancer, Metastatic Colorectal Cancer, Thymalfasin","enrollment":""},{"nctId":"NCT02611960","phase":"PHASE3","title":"Study of Pembrolizumab (MK-3475) in Platinum Pre-treated Recurrent/Metastatic Nasopharyngeal Cancer (MK-3475-122/KEYNOTE-122)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2016-04-18","conditions":"Nasopharyngeal Neoplasms","enrollment":233},{"nctId":"NCT00258310","phase":"PHASE2","title":"Ph II Long Term/Low Dose Xeloda in Head and Neck Squamous Cell Carcinoma After Surgery, Radiation & or Chemo","status":"COMPLETED","sponsor":"Barbara Ann Karmanos Cancer Institute","startDate":"2003-12","conditions":"Head and Neck Cancer","enrollment":35},{"nctId":"NCT02335411","phase":"PHASE2","title":"A Study of Pembrolizumab (MK-3475) in Participants With Recurrent or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma (MK-3475-059/KEYNOTE-059)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2015-02-03","conditions":"Gastric Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma","enrollment":318},{"nctId":"NCT02574455","phase":"PHASE3","title":"Trial of Sacituzumab Govitecan in Participants With Refractory/Relapsed Metastatic Triple-Negative Breast Cancer (TNBC)","status":"COMPLETED","sponsor":"Gilead Sciences","startDate":"2017-11-07","conditions":"Breast Cancer","enrollment":529},{"nctId":"NCT02595320","phase":"PHASE2","title":"Capecitabine in Metastatic Breast and GI Cancers","status":"UNKNOWN","sponsor":"Qamar Khan","startDate":"2015-10-05","conditions":"Breast Cancer, Gastrointestinal Cancer","enrollment":200},{"nctId":"NCT04859582","phase":"PHASE3","title":"Pembrolizumab (MK-3475) Plus Chemotherapy Versus Placebo Plus Chemotherapy in Participants Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma (MK-3475-859/KEYNOTE-859)-China Extension","status":"WITHDRAWN","sponsor":"Merck Sharp & Dohme LLC","startDate":"2018-11-08","conditions":"Stomach Neoplasms","enrollment":""},{"nctId":"NCT02555657","phase":"PHASE3","title":"Study of Single Agent Pembrolizumab (MK-3475) Versus Single Agent Chemotherapy for Metastatic Triple Negative Breast Cancer (MK-3475-119/KEYNOTE-119)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2015-10-13","conditions":"Metastatic Triple Negative Breast Cancer","enrollment":622},{"nctId":"NCT01295086","phase":"NA","title":"Taxotere®, Eloxatin® and Xeloda® (TEX) in Combination With Herceptin® as Treatment for HER2 Positive Non-resectable Cancer","status":"COMPLETED","sponsor":"Odense University Hospital","startDate":"2011-03","conditions":"Adenocarcinoma","enrollment":27},{"nctId":"NCT01369433","phase":"NA","title":"A Rollover Protocol to Allow Continued Access to Tivozanib (AV 951) for Subjects Enrolled in Other Tivozanib Protocols","status":"TERMINATED","sponsor":"AVEO Pharmaceuticals, Inc.","startDate":"2010-06","conditions":"Solid Tumors","enrollment":225},{"nctId":"NCT04420871","phase":"PHASE1","title":"Pharmacokinetic and Safety Comparison of Two Capecitabine Tablets in Patients With Colorectal or Breast Cancer","status":"COMPLETED","sponsor":"The Affiliated Hospital of Qingdao University","startDate":"2018-12-10","conditions":"Patient Participation","enrollment":48},{"nctId":"NCT01836432","phase":"PHASE3","title":"Immunotherapy Study in Borderline Resectable or Locally Advanced Unresectable Pancreatic Cancer","status":"TERMINATED","sponsor":"NewLink Genetics Corporation","startDate":"2013-05","conditions":"Pancreatic Cancer, Pancreatic Carcinoma Non-resectable, Locally Advanced Malignant Neoplasm","enrollment":302},{"nctId":"NCT01633203","phase":"","title":"Observational Study of Perioperative Chemotherapy in Gastric Cancer","status":"COMPLETED","sponsor":"Grupo Oncologico Cooperativo Chileno de Investigation","startDate":"2010-08","conditions":"Gastric Cancer","enrollment":61},{"nctId":"NCT01187212","phase":"PHASE2","title":"Sorafenib Trial in Advanced and/or Recurrent Gastric Adenocarcinoma: Treatment Evaluation: STARGATE","status":"COMPLETED","sponsor":"Asan Medical Center","startDate":"2010-08","conditions":"Malignant Neoplasm of Stomach, Effects of Chemotherapy","enrollment":195},{"nctId":"NCT00398398","phase":"PHASE2","title":"Study of XELOX With Cetuximab in Advanced Gastric Cancer","status":"COMPLETED","sponsor":"Asan Medical Center","startDate":"2006-11","conditions":"Gastric Cancer","enrollment":44},{"nctId":"NCT01045538","phase":"PHASE1, PHASE2","title":"Study of Vorinostat Plus Capecitabine (X) and Cisplatin (P) for 1st Line Treatment of Metastatic or Recurrent Gastric Cancer: Zolinza+XP","status":"COMPLETED","sponsor":"Asan Medical Center","startDate":"2010-02","conditions":"Gastric Cancer, Histone Deacetylase Inhibitor","enrollment":45},{"nctId":"NCT03185988","phase":"PHASE2","title":"Anti-HER2 Therapy in Patients of HER2 Positive Metastatic Carcinoma of Digestive System","status":"UNKNOWN","sponsor":"Shen Lin","startDate":"2017-07-01","conditions":"Targeted Therapy, HER2, Biliary Tract Cancer","enrollment":100},{"nctId":"NCT04008511","phase":"PHASE1, PHASE2","title":"Regorafenib and XELOX as 2nd Line Treatment in Metastatic Colorectal Cancer","status":"UNKNOWN","sponsor":"China Medical University, China","startDate":"2019-07","conditions":"Metastatic Colorectal Cancer","enrollment":54},{"nctId":"NCT02581501","phase":"PHASE1","title":"Prospective Phase I Study of GAX for Metastatic Pancreatic Cancer","status":"WITHDRAWN","sponsor":"Stamford Hospital","startDate":"2016-02","conditions":"Pancreatic Cancer","enrollment":""},{"nctId":"NCT02297230","phase":"PHASE1, PHASE2","title":"Locally Advanced Breast Cancer: Individualized Treatment Based On Tumor Molecular Characteristics","status":"TERMINATED","sponsor":"NYU Langone Health","startDate":"2002-06","conditions":"Breast Cancer","enrollment":44},{"nctId":"NCT00551213","phase":"PHASE2","title":"A Study to Determine the Activity of Robatumumab (SCH 717454, MK-7454) in Participants With Relapsed or Recurrent Colorectal Cancer (P04721, MK-7454-003)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2007-11-21","conditions":"Colorectal Cancer","enrollment":67},{"nctId":"NCT01887288","phase":"PHASE2","title":"Capecitabine With Digoxin for Metastatic Breast Cancer","status":"TERMINATED","sponsor":"Western Regional Medical Center","startDate":"2013-04","conditions":"Metastatic Breast Cancer","enrollment":16},{"nctId":"NCT01234324","phase":"PHASE2","title":"ECX + Panitumumab vs. ECX Alone in Locally Advanced Gastric Cancer or Cancer of the Gastroesophageal Junction","status":"COMPLETED","sponsor":"AIO-Studien-gGmbH","startDate":"2010-10","conditions":"Stomach Neoplasms, Gastroesophageal Junction Neoplasms","enrollment":171},{"nctId":"NCT00833859","phase":"PHASE2","title":"Neoadjuvant Gemcitabine, Docetaxel, and Capecitabine in Combination With Stereotactic Radiosurgery","status":"TERMINATED","sponsor":"H. Lee Moffitt Cancer Center and Research Institute","startDate":"2009-03","conditions":"Pancreatic Neoplasms","enrollment":2},{"nctId":"NCT00763516","phase":"NA","title":"Proton Radiation for Resectable Carcinoma of the Pancreas","status":"COMPLETED","sponsor":"University of Florida","startDate":"2009-02","conditions":"Pancreatic Cancer","enrollment":8},{"nctId":"NCT00685763","phase":"NA","title":"Proton Therapy for Unresectable Cancer (CA) of Pancreas","status":"COMPLETED","sponsor":"University of Florida","startDate":"2008-03","conditions":"Pancreatic Cancer","enrollment":13},{"nctId":"NCT01722162","phase":"PHASE2","title":"Levocetirizine + Capecitabine + Bevacizumab for Patients With Refractory Colorectal Cancer","status":"COMPLETED","sponsor":"Washington University School of Medicine","startDate":"2013-04","conditions":"Colorectal Neoplasms","enrollment":47},{"nctId":"NCT03117855","phase":"PHASE1","title":"Capecitabine and Y-90 Radioembolization in Treating Patients With Advanced Bile Duct Cancer in the Liver That Cannot Be Removed by Surgery","status":"WITHDRAWN","sponsor":"City of Hope Medical Center","startDate":"2016-12","conditions":"Bile Duct Adenocarcinoma, Stage III Intrahepatic Cholangiocarcinoma, Stage IVA Intrahepatic Cholangiocarcinoma","enrollment":""},{"nctId":"NCT01801085","phase":"","title":"Nursing and Pharmacy Time for Delivering Xeloda® Versus 5-Fluoruracil Regimens","status":"TERMINATED","sponsor":"Vivian Wing Yan Lee","startDate":"2011-10","conditions":"Colorectal Cancer","enrollment":21},{"nctId":"NCT00399035","phase":"PHASE3","title":"Cediranib (AZD2171, RECENTIN™) in Addition to Chemotherapy in Patients With Untreated Metastatic Colorectal Cancer","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2006-11","conditions":"Metastatic Colorectal Cancer","enrollment":1254},{"nctId":"NCT00977379","phase":"PHASE2","title":"A Study of Whole Brain Radiation Therapy and Capecitabine in Breast Cancer Participants With Newly Diagnosed Brain Metastasis","status":"TERMINATED","sponsor":"Hoffmann-La Roche","startDate":"2009-08","conditions":"Breast Cancer","enrollment":24},{"nctId":"NCT01493336","phase":"PHASE1","title":"A Study of Capecitabine Rapid Disintegrating Tablets (RDT) Versus Commercial Xeloda in Patients With Solid Tumours","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2012-05","conditions":"Breast Cancer, Colorectal Cancer","enrollment":37},{"nctId":"NCT01077726","phase":"PHASE2","title":"A Study of Xeloda (Capecitabine) in Breast Cancer Patients With Central Nervous System (CNS) Progression","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2010-01","conditions":"Breast Cancer","enrollment":3},{"nctId":"NCT00454636","phase":"PHASE2","title":"A Study of Xeloda (Capecitabine) in Combination With Chemotherapy in Patients With Advanced and/or Metastatic Gastric Cancer.","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2007-03","conditions":"Gastric Cancer","enrollment":158},{"nctId":"NCT01725386","phase":"","title":"An Observational Study of Xeloda (Capecitabine) in Participants With Metastatic or Advanced Breast Cancer","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2011-03","conditions":"Breast Cancer","enrollment":274},{"nctId":"NCT01399190","phase":"","title":"An Observational Study of Avastin (Bevacizumab) in Combination With Xeloda (Capecitabine) And Oxaliplatin in Patients With Colorectal Cancer","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2011-07","conditions":"Colorectal Cancer","enrollment":68},{"nctId":"NCT00868634","phase":"PHASE3","title":"Capecitabine and Bevacizumab ± Vinorelbine in Metastatic Breast Cancer","status":"COMPLETED","sponsor":"iOMEDICO AG","startDate":"2009-02","conditions":"Metastatic Breast Cancer","enrollment":600},{"nctId":"NCT00796718","phase":"PHASE2","title":"A Study of Xeloda (Capecitabine) Plus Radiotherapy in Participants With Locally Advanced Rectal Cancer","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2008-10","conditions":"Colorectal Cancer","enrollment":62},{"nctId":"NCT00996333","phase":"PHASE2","title":"Study of Gemzar®, Taxotere®, and Xeloda® (GTX) in Patients With Metastatic Pancreatic Cancer (Stage IVB)","status":"COMPLETED","sponsor":"Columbia University","startDate":"2003-06","conditions":"Metastatic Pancreatic Cancer","enrollment":46},{"nctId":"NCT00869258","phase":"PHASE2","title":"Study for Inoperable Non-Metastatic Pancreatic CA (Stage IVA) With Neoadjuvant GTX, and Radiation With Gemzar","status":"COMPLETED","sponsor":"Columbia University","startDate":"2005-06","conditions":"Pancreatic Cancer Stage IVA","enrollment":32},{"nctId":"NCT00130936","phase":"PHASE1, PHASE2","title":"Study of Epirubicin (Pharmorubicin®), Carboplatin (Paraplatin®) and Capecitabine (Xeloda®) (ECC) in the Treatment of Unresectable Locally Advanced or Metastatic Gastric/Gastroesophageal Junction Cancer With Pharmacogenetic Correlates","status":"TERMINATED","sponsor":"AHS Cancer Control Alberta","startDate":"2005-10","conditions":"Gastric Cancer, Esophageal Cancer, Tumors","enrollment":50},{"nctId":"NCT00177255","phase":"PHASE2","title":"A Study of Docetaxel in Combination With Capecitabine in Stomach and Esophagus Cancers","status":"TERMINATED","sponsor":"University of Pittsburgh","startDate":"2005-04","conditions":"Cancer","enrollment":40},{"nctId":"NCT01641458","phase":"PHASE4","title":"Pharmacology-driven Dosing of Fluoropyrimidines in Cancer Patients","status":"COMPLETED","sponsor":"Cantonal Hospital of St. Gallen","startDate":"2012-10","conditions":"Colorectal Cancer","enrollment":37},{"nctId":"NCT00577031","phase":"PHASE4","title":"OBELIX Study: A Study of Avastin (Bevacizumab) in Combination With XELOX in Patients With Metastatic Cancer of the Colon or Rectum.","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2008-02","conditions":"Colorectal Cancer","enrollment":205},{"nctId":"NCT01754623","phase":"PHASE2","title":"GTX-RT in Borderline Resectable Pancreatic Cancer","status":"TERMINATED","sponsor":"H. Lee Moffitt Cancer Center and Research Institute","startDate":"2013-02","conditions":"Pancreatic Cancer","enrollment":9},{"nctId":"NCT00477711","phase":"PHASE2","title":"A Study of Cetuximab(Erbitux) With Cisplatin and Capecitabine(Xeloda)as 1st Line Treatment in the Advanced Gastric Cancer","status":"COMPLETED","sponsor":"Peking University","startDate":"2007-03","conditions":"Gastric Cancer","enrollment":41},{"nctId":"NCT00842491","phase":"PHASE2","title":"Study of Endostar With Cisplatin and Capecitabine as 1st Line Treatment in the Advanced Gastric Cancer","status":"COMPLETED","sponsor":"Peking University","startDate":"2008-11","conditions":"Advanced Gastric Cancer","enrollment":45},{"nctId":"NCT01157052","phase":"PHASE1","title":"Oxaliplatin Pharmacokinetics With and Without Ca2+/MG2+ Infusion in Colorectal Cancer Patients","status":"UNKNOWN","sponsor":"AHS Cancer Control Alberta","startDate":"2015-01","conditions":"Neoplasms, Colorectal, Colorectal Cancer, Colorectal Carcinoma","enrollment":15},{"nctId":"NCT00372944","phase":"PHASE2","title":"AZD6244 vs. Capecitabine (Xeloda®) in Patients With Advanced or Metastatic Pancreatic Cancer, Who Have Failed First Line Gemcitabine Therapy","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2006-08","conditions":"Pancreatic Cancer","enrollment":70},{"nctId":"NCT00087152","phase":"PHASE2","title":"S0338, Imatinib Mesylate and Capecitabine in Treating Women With Progressive Stage IV Breast Cancer","status":"COMPLETED","sponsor":"National Cancer Institute (NCI)","startDate":"2004-06","conditions":"Breast Cancer","enrollment":27},{"nctId":"NCT01434147","phase":"PHASE2","title":"Preoperative Combined Induction Chemotherapy With Capecitabine, Oxaliplatin, Bevacizumab and Radiotherapy","status":"COMPLETED","sponsor":"Austrian Breast & Colorectal Cancer Study Group","startDate":"2011-10","conditions":"Rectal Cancer","enrollment":25},{"nctId":"NCT00258284","phase":"PHASE2","title":"Capecitabine and Docetaxel in Treating Patients With Metastatic Prostate Cancer","status":"COMPLETED","sponsor":"Barbara Ann Karmanos Cancer Institute","startDate":"2003-08","conditions":"Prostate Cancer","enrollment":30},{"nctId":"NCT01118377","phase":"PHASE2","title":"A Study of Capecitabine (Xeloda®) and Concomitant Radiation Therapy in Children With Newly Diagnosed Brainstem Gliomas","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2007-05","conditions":"Brainstem Glioma","enrollment":45},{"nctId":"NCT01306630","phase":"PHASE1","title":"A Trial of Tivozanib (AV-951) in Combination With Capecitabine (Xeloda®) in Subjects With Advanced Solid Tumors","status":"COMPLETED","sponsor":"AVEO Pharmaceuticals, Inc.","startDate":"2010-11","conditions":"Advanced Solid Tumors, Locally Advanced or Metastatic Breast or Colorectal Cancer","enrollment":24},{"nctId":"NCT01067053","phase":"PHASE2","title":"Efficacy/Safety Study of Bevacizumab,Capecitabine,Oxaliplatin to Metastatic Colorectal Adenocarcinoma Elderly Patients.","status":"UNKNOWN","sponsor":"Grupo Espanol Multidisciplinario del Cancer Digestivo","startDate":"2009-11","conditions":"Metastatic Colorectal Cancer","enrollment":69},{"nctId":"NCT00112918","phase":"PHASE3","title":"Combination Chemotherapy With or Without Bevacizumab in Treating Patients Who Have Undergone Surgery for High Risk Stage II or Stage III Colon Cancer","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2004-12","conditions":"Colorectal Cancer","enrollment":3451},{"nctId":"NCT00795678","phase":"","title":"Chemotherapeutic Agents in Brain/Breast","status":"COMPLETED","sponsor":"Case Comprehensive Cancer Center","startDate":"2008-09","conditions":"Breast Cancer, Metastatic Cancer","enrollment":10},{"nctId":"NCT00476827","phase":"PHASE2","title":"A Phase II Safety and Tolerability Study of Bevacizumab When Added to Single-agent Chemotherapy to Treat Patient With Breast Cancer Metastatic to Brain","status":"TERMINATED","sponsor":"Duke University","startDate":"2007-05","conditions":"Breast Cancer","enrollment":16},{"nctId":"NCT00077857","phase":"PHASE2","title":"A Study to Assess Capecitabine (Xeloda®) in Patients With Locally Advanced or Metastatic Breast Cancer","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2003-07","conditions":"Breast Cancer","enrollment":470},{"nctId":"NCT00087334","phase":"PHASE1, PHASE2","title":"Capecitabine, Oxaliplatin, and Gefitinib in Treating Patients With Metastatic Colorectal Cancer","status":"TERMINATED","sponsor":"Roswell Park Cancer Institute","startDate":"2004-01","conditions":"Colorectal Cancer","enrollment":10},{"nctId":"NCT00227656","phase":"PHASE2","title":"Capecitabine and Pegylated Interferon Alfa-2a in Treating Patients With Recurrent or Progressive Brain Metastases Due to Breast Cancer","status":"TERMINATED","sponsor":"M.D. Anderson Cancer Center","startDate":"2005-09","conditions":"Breast Cancer, Metastatic Cancer","enrollment":2},{"nctId":"NCT00480584","phase":"PHASE1","title":"A Phase I Trial of Capecitabine in Combination With Gemcitabine and Erlotinib for Advanced Pancreatic Cancer","status":"COMPLETED","sponsor":"H. Lee Moffitt Cancer Center and Research Institute","startDate":"2007-04","conditions":"Metastatic Pancreatic Carcinoma","enrollment":20},{"nctId":"NCT00658840","phase":"PHASE2","title":"Concurrent Chemo-radiotherapy With Capecitabine for Unresectable Locally Advanced Pancreatic Carcinoma","status":"UNKNOWN","sponsor":"National Cancer Center, Korea","startDate":"2006-06","conditions":"Pancreatic Cancer","enrollment":55},{"nctId":"NCT00689702","phase":"PHASE2","title":"Cetuximab (Erbitux®), Capecitabine and Radiotherapy in Neoadjuvant Treatment of Patients With Rectal Cancer","status":"UNKNOWN","sponsor":"Institute of Oncology Ljubljana","startDate":"2007-02","conditions":"Rectal Cancer","enrollment":43},{"nctId":"NCT00973778","phase":"PHASE2","title":"A Study for Short Preoperative Chemoradiotherapy for Resectable Rectal Carcinoma","status":"UNKNOWN","sponsor":"Shanghai Jiao Tong University School of Medicine","startDate":"2009-07","conditions":"Chemoradiotherapy","enrollment":62},{"nctId":"NCT00873353","phase":"PHASE2","title":"Trial to Evaluate the Efficacy and Safety of Tarceva and Capecitabine in Advanced Pancreatic Cancer Patients","status":"COMPLETED","sponsor":"Grupo Gallego de Investigaciones Oncologicas","startDate":"2008-03","conditions":"Metastatic Adenocarcinoma of the Pancreas","enrollment":32},{"nctId":"NCT00114153","phase":"PHASE1","title":"Carboplatin, Capecitabine, and Radiation Therapy in Treating Patients With Stage III or Stage IV Head and Neck Cancer","status":"COMPLETED","sponsor":"University of Virginia","startDate":"2003-06","conditions":"Head and Neck Cancer","enrollment":48},{"nctId":"NCT00853684","phase":"PHASE2","title":"Oxaliplatin, Capecitabine and Endostar as First Line Treatment for Patients With Advanced Colorectal Cancer","status":"UNKNOWN","sponsor":"Shanghai Jiao Tong University School of Medicine","startDate":"2009-02","conditions":"Advanced Colorectal Cancer","enrollment":44},{"nctId":"NCT00201435","phase":"PHASE2, PHASE3","title":"Weekly Taxol Plus Xeloda® vs Taxotere q3wk Plus Xeloda® in the Treatment of Metastatic BC","status":"COMPLETED","sponsor":"Norwegian Breast Cancer Group","startDate":"2005-03","conditions":"Breast Neoplasm","enrollment":224},{"nctId":"NCT00669370","phase":"PHASE2","title":"Biweekly Docetaxel in Combination With Capecitabine as First-Line Treatment in Patients With Advanced Gastric Cancer","status":"UNKNOWN","sponsor":"University of Turku","startDate":"2006-06","conditions":"Stomach Neoplasms","enrollment":50},{"nctId":"NCT00635323","phase":"PHASE2","title":"Safety And Efficacy Of Irinotecan Plus Capecitabine As First-Line Treatment In Asian Subjects With Hepatocellular Carcinoma","status":"COMPLETED","sponsor":"Pfizer","startDate":"2002-11","conditions":"Carcinoma, Hepatocellular","enrollment":73}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":206,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Xeloda","Capecitabine","Carboplatin","Docetaxel","Xeloda®"],"phase":"marketed","status":"active","brandName":"Capecitabine (Xeloda®)","genericName":"Capecitabine (Xeloda®)","companyName":"National Cancer Center, Korea","companyId":"national-cancer-center-korea","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Capecitabine is a prodrug that is converted to fluorouracil in tumor tissue, where it inhibits thymidylate synthase and gets incorporated into DNA and RNA to disrupt cancer cell growth. Used for Metastatic colorectal cancer, Metastatic breast cancer, Gastric cancer.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}